Blinatumomab Plus Tyrosine Kinase Inhibitors With No Chemotherapy In Bcr-Abl-Positive Or Ikzf1-Deleted Or Flt3-Itd-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients: High Molecular Remission Rate And Toxicity Profile
BLOOD（2017）
关键词
lymphoblastic leukemia,tyrosine kinase,chemotherapy,bcr-abl-positive,itd-positive
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要